Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Apollo Endosurgery (NASDAQ:APEN) Stock Price

Headlines about Apollo Endosurgery (NASDAQ:APEN) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Apollo Endosurgery earned a media sentiment score of 0.05 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 44.9645643495478 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Apollo Endosurgery (NASDAQ APEN) opened at $6.10 on Friday. Apollo Endosurgery has a one year low of $3.55 and a one year high of $15.40. The company has a quick ratio of 2.00, a current ratio of 2.54 and a debt-to-equity ratio of 0.58.

Apollo Endosurgery (NASDAQ:APEN) last released its earnings results on Thursday, October 26th. The biotechnology company reported ($0.32) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.39) by $0.07. Apollo Endosurgery had a negative return on equity of 98.11% and a negative net margin of 62.31%. equities analysts anticipate that Apollo Endosurgery will post -1.96 earnings per share for the current fiscal year.

APEN has been the topic of several research analyst reports. Northland Securities reiterated a “buy” rating and issued a $12.00 price objective on shares of Apollo Endosurgery in a report on Monday, December 4th. Zacks Investment Research upgraded Apollo Endosurgery from a “hold” rating to a “buy” rating and set a $4.75 price objective on the stock in a report on Thursday, November 2nd. Roth Capital set a $10.00 price objective on Apollo Endosurgery and gave the company a “buy” rating in a report on Thursday, January 4th. Finally, ValuEngine upgraded Apollo Endosurgery from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 3rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. Apollo Endosurgery presently has an average rating of “Hold” and an average target price of $9.44.

In other Apollo Endosurgery news, VP Bret Schwartzhoff acquired 9,500 shares of the stock in a transaction dated Tuesday, November 7th. The stock was acquired at an average cost of $4.24 per share, with a total value of $40,280.00. Following the transaction, the vice president now owns 15,631 shares in the company, valued at approximately $66,275.44. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Stonepine Capital, L.P. acquired 45,434 shares of the stock in a transaction dated Wednesday, December 20th. The shares were acquired at an average cost of $4.50 per share, with a total value of $204,453.00. Following the completion of the transaction, the insider now owns 2,410,141 shares in the company, valued at approximately $10,845,634.50. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 273,386 shares of company stock valued at $1,328,331. Insiders own 74.20% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/21/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-apollo-endosurgery-apen-stock-price.html.

About Apollo Endosurgery

Apollo Endosurgery, Inc, formerly Lpath, Inc, is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries.

Insider Buying and Selling by Quarter for Apollo Endosurgery (NASDAQ:APEN)

Receive News & Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply